Κλινικές Μελέτες
Modification of metabolic syndrome parameters following the administration of polyglucosamine L112. Results of a subgroup analysis of subjects enrolled in a double blind randomised placebo controlled clinical investigation
This is the first study conducted in order to evaluate the efficacy of polyglucosamine L112 on body weight, insulin resistance, and cholesterol in patients with metabolic syndrome. The studies conducted to date have considered only the efficacy of chitosans on MS and were limited to blood glucose. Polyglucosamine L112 instead consists of standardized polymers characterized by >80% degree of deacetylation and a peak molecular weight (Mp) of about 65 KDa and was shown active on body weight, cholesterol levels and insulin resistance. This study demonstrated that the subgroup of patients suffering from MS and treated with L112 showed a significant improvement in 50% of the subjects despite the product being the only treatment administered for MS.
Intestinal fat absorption by a polyglucosamine biopolymer controls lipids and reduces the progression of early, subclinical atherosclerosis.
Formoline shows positive effects of on the lipid profile, weight, fat mass and oxidative stress due to the combination of IFAS and a mild diet. These activities showed a significant protection of arterial wall structures measured with the ultrasound scanning in a two years period of management and in subjects with subclinical conditions.
A Randomized Double-Blind Placebo-Controlled Clinical Study to Evaluate the Effect on the Weight of a Medical Device with Polyglucosamine L112 in a Group of Overweight and Obese Subjects.
Formoline acts as a safe medical device, is not absorbed, and binds lipids in the upper gastrointestinal tract, reducing their availability, with a significant activity on the reduction of BW, insulin resistance, and cholesterol levels without the modification of fat-soluble vitamins.
Long-Term Treatment of Overweight and Obesity with Polyglucosamine (PG L112): Randomized Study Compared with Placebo in Subjects after Caloric Restriction
Short-term treatment of overweight and obesity with polyglucosamine (PG) was
found to be more effective than placebo and orlistat in double-blind clinical studies.
Information for professionals
Guideline-based use and efficacy of the lipid binders formoline L112 and formoline L112 EXTRA in the therapy of overweight and obesity
Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity
The efficacy of a non-prescription drug to support weight loss programs has yet to be compared.
This clinical trial investigates the comparability of orlistat 60 milligram (mg) and polyglucosamine.
![A single oral dose of a polyglucosamine influences the bioavailability of [9-(14)C]-Oleic acid in adult female Göttingen minipigs photo](https://formoline.gr/wp-content/uploads/2023/02/A-single-oral-dose-of-a-polyglucosamine-influences-the-bioavailability-of-9-14C-Oleic-acid-in-adult-female-Gottingen-minipigs.png)
A single oral dose of a polyglucosamine influences the bioavailability of [9-14C]- Oleic acid in adult female Göttingen minipigs
The objective of this study is to investigate the influence of polyglucosamine on the bioavailability of the model compound [9-14C]-oleic acid in female Göttingen minipigs.
Efficacy of polyglucosamine for weight loss—confirmed in a randomized double-blind, placebo-controlled clinical investigation
The purpose of this clinical study was to ascertain whether low molecular weight chitosan polyglucosamine is able to produce significantly better weight loss than placebo.
Οδηγίες χρήσης
Διαβάστε προσεκτικά αυτές τις οδηγίες χρήσης πριν τη λήψη του formoline L112 EXTRA.